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cardiolipin and anti-B2 glycoprotein I antibodies were positive in 47.1% and
52.8% of cases respectively. Anticoagulant therapy was prescribed in throm-
botic cases. Pericarditis were treated with corticosteroids and patient with
myoarditis had both corticosteroid and immunosuppressant agent.
Conclusion DVP were the most frequent vascular manifestation in patients
with APLS. Cardiac involvements are rare but serious. They can affect all
parts of the heart but cardiac valvulopathy and coronary artery thrombosis are
the most frequent.
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Aim To describe the clinical and echocardiographic aspects of HIV-
infected patients. 
Method this descriptive and analytical study was conducted from 2008 to
2012 in the cardiology department at the University Hospital of Brazzaville.
Results one hundred and thirteen patients were included, 75 women
(66.4%). There were 46 (40.7%) known HIV patients, and 40 (35.4%) were
on antiretroviral treatment. Heart failure was noted in 59 cases (52.2%) which
15 cases (13.3%) of pulmonary acute oedema. The mean ejection fraction was
54.8±16.2% (range: 17-80), and the ejection fraction was lowered in 39 cases
(34.5%). Pulmonary hypertension was present in 8 cases (7.1%). The main
pathologies were myocarditis (n=33; 29.2%), dilated cardiomyopathy (n=27;
23.9%), myopericarditis (n=20; 17.7%) and tuberculous pericarditis (n=30;
26.5%). The death was recorded in 16 cases. Average CD4 count, ejection
fraction, left ventricle diameter and right ventricle diameter were lower in
deceased patients, no statistical difference. 
Conclusion untreated HIV exhibit more cardiovascular complications.
Mortality is due to several comorbidities. For limiting these complications,
prevention and antiretroviral treatment actually poorly used, are required.
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Glycogen storage disease type III (GSD III) is an autosomal recessive dis-
ease, due to deficiency of glycogen debranching enzyme (GDE), a key
enzyme involved in glycogen degradation. Clinical presentation includes hep-
atomegaly, myopathy, hypoglycemia and cardiomyopathy.
The cardiac natural history of patients with GSD III and its relationship
with genetic abnormalities is not well known. We performed a longitudinal
study in order to describe the natural history of heart involvement in patients
with glycogen GSD III.
47 patients were included our study (16 male/31 female). Mean age was
25.7 years ±15.4. 
All patients were in sinus rhythm expect one patient (atrial fibrillation). 9
patients/ 47 disclosed abnormal repolarization. Electrical left ventricular
hypertrophy was found in 22 patients /47.
Heart failure was found in 10 patients/47 and 2 patients/47 disclosed a left
ventricular dysfunction. Hypertrophic cardiomyopathy was found in 23 patients
/47; and 4 patients/47 disclosed obstructive hypertrophic cardiomyopathy.
Patients with hypertrophic cardiomyopathy depicted 2 codon-stops (p 0.03). 
In conclusion, hypertrophic cardiomyopathy is frequent in patients with
GSD III.
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Introduction Sarcoidosis is a systemic granulomatous disease of unknown
etiology. Cardiac involvements in patients with sarcoidosis are rare with an
estimated prevalence of 7%. These serious involvements are hard to diagnose
at early stage of disease.
Patients and Methods We performed a retrospective study of patients’
files diagnosed with sarcoidosis in the Internal Medicine Department of Rabta
University Hospital in Tunis. The diagnosis of sarcoidosis was based on clin-
ical, paraclinical and histological criteria. Cardiac involvements were con-
firmed by the electrocardiogram and echocardiography.
Results Cardiac involvement (CI) was found in seven patients among 138
with sarcoidosis (5%). They were 6 females and one male with a mean age at
diagnosis of 49 years. Electrical disorders such as bundel branch block were
seen in two cases. First degree atrioventricular block was noted in two cases.
Ventricular hypertrophy was check out in two cases by electrocardiography
and ultrasound. Mitral regurgitation with a flutter was noted in one patient and
pericardial effusion with a normal ventricular function in another case. Only
one patient was clinically symptomatic, he complained of palpitations. Thal-
lium 201 scintigraphy was performed in one case and objectived reversible
ischemia of the inferior and latero-inferior walls of myocardium. Other mani-
festations of sarcoidosis were dominantly associated to CI such as lung dis-
ease, which was found in all patients. Skin and neurological involvement were
observed, each in three cases. Hepatosplenic involvements were noted in two
patients and otorhinolaryngology involvements in one case. All patients
received initially high dose of corticosteroids. Four of the patients had a good
response to treatment and three were lost to follow up. 
Conclusion Cardiac involvements in sarcoidosis are rare but serious, an early
diagnosis and treatment with corticosteroid may rapidly improve patients.
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Introduction Amyloidosis is a rare disease. Some types of amyloidosis
may significantly affect the heart; abnormal monoclonal light-chain s (AL),
transthyretin-related hereditary (TTR) and senile amyloidosis.
Patients and Methods Patients’ files with amylodosis were studied (hospi-
talized in an internal medicine department, from 2000 to 2013), only patients
with cadiac involvement were enrolled. 
Results Fourteen patients with cardiac amyloidosis were included; sex ratio
M/F was 1. Mean age at diagnosis was 60.6 years (range 36-78 years). Car-
diac manifestations revealed amyloidosis in 42.8% of cases. Patient com-
plained of fatigue (50%), dyspnea (35.7%), chest pain (28.5%) and palpitation
(14.2%). One patient presented with recurrent syncope attack due to parox-
ysmal atrioventricular block. Four patients had cardiac failure at amylodosis
diagnosis. 
Amyloidosis was systemic in all cases; Kidney localization (9 cases), hep-
atomegaly (6 cases), and macroglossia (4 cases). N-terminal pro-brain natri-
